[go: up one dir, main page]

MX2011012114A - Solucion farmaceutica bebible de telmisartan. - Google Patents

Solucion farmaceutica bebible de telmisartan.

Info

Publication number
MX2011012114A
MX2011012114A MX2011012114A MX2011012114A MX2011012114A MX 2011012114 A MX2011012114 A MX 2011012114A MX 2011012114 A MX2011012114 A MX 2011012114A MX 2011012114 A MX2011012114 A MX 2011012114A MX 2011012114 A MX2011012114 A MX 2011012114A
Authority
MX
Mexico
Prior art keywords
solution
pharmaceutical oral
pharmaceutical
telmisartan
telmisartan solution
Prior art date
Application number
MX2011012114A
Other languages
English (en)
Other versions
MX346039B (es
Inventor
Stefan Lehner
Detlef Mohr
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42340411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011012114(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of MX2011012114A publication Critical patent/MX2011012114A/es
Publication of MX346039B publication Critical patent/MX346039B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una solución farmacéutica, de preferencia una solución farmacéutica bebible del principio activo Telmisartan con un valor del pH mayor que 10 que contiene, adicionalmente, uno o más azúcar-alcoholes añadidos para mejorar el sabor y la conservabilidad, en donde los azúcaralcoholes o la solución farmacéutica presentan una proporción máxima de 1000 ppm en azúcares reductores.
MX2011012114A 2009-05-20 2010-05-19 Solucion farmaceutica bebible de telmisartan. MX346039B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09160771 2009-05-20
PCT/EP2010/056895 WO2010133638A1 (de) 2009-05-20 2010-05-19 Pharmazeutische telmisartan-trinklösung

Publications (2)

Publication Number Publication Date
MX2011012114A true MX2011012114A (es) 2011-12-16
MX346039B MX346039B (es) 2017-03-03

Family

ID=42340411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012114A MX346039B (es) 2009-05-20 2010-05-19 Solucion farmaceutica bebible de telmisartan.

Country Status (19)

Country Link
US (3) US8871795B2 (es)
EP (1) EP2432452B1 (es)
JP (1) JP5612674B2 (es)
KR (1) KR20120015325A (es)
CN (1) CN102458363A (es)
AR (1) AR076913A1 (es)
AU (1) AU2010251194B2 (es)
BR (1) BRPI1013037A2 (es)
CA (1) CA2761576C (es)
CL (1) CL2011002926A1 (es)
CO (1) CO6470844A2 (es)
DK (1) DK2432452T3 (es)
ES (1) ES2598490T3 (es)
MX (1) MX346039B (es)
NZ (1) NZ597049A (es)
PL (1) PL2432452T3 (es)
SG (1) SG176585A1 (es)
TW (1) TW201109040A (es)
WO (1) WO2010133638A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
MX346039B (es) * 2009-05-20 2017-03-03 Boehringer Ingelheim Vetmedica Gmbh Solucion farmaceutica bebible de telmisartan.
JP6377426B2 (ja) * 2013-06-21 2018-08-22 わかもと製薬株式会社 水性医薬組成物
JP6344678B2 (ja) * 2013-09-27 2018-06-20 キョーリンリメディオ株式会社 テルミサルタン含有製剤及びその製造方法
SI3648761T1 (sl) * 2017-07-07 2024-07-31 Boehringer Ingelheim Vetmedica Gmbh Telmisartan za profilakso ali zdravljenje hipertenzije pri mačkah
JP2025506686A (ja) * 2022-02-17 2025-03-13 ウールジー・ファーマシューティカルズ・インコーポレイテッド ファスジルの味マスキング経口製剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1023027B (de) 1953-07-10 1958-01-23 Hoffmann La Roche Verfahren zur Herstellung von Polyendialdehyden
US4448778A (en) * 1981-08-03 1984-05-15 Ici Americas Inc. Maltitol containing gel base systems
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
JP3862295B2 (ja) 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
HUP9801593A2 (hu) 1995-04-07 1999-01-28 Novartis Ag. Benazeprilt vagy benazeprilátot és valzartánt tartalmazó kombinált gyógyszerkészítmények és azok alkalmazása
EP0910375B1 (en) 1996-06-24 2002-05-02 Merck & Co., Inc. A composition of enalapril and losartan
JPH11315034A (ja) 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
DE69914460T2 (de) 1998-03-04 2004-10-28 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter wirkstoffabgabe für aii antagonisten, ihre herstellung und verwendung
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE19901921C2 (de) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP2006516020A (ja) 2002-08-28 2006-06-15 キュリス インコーポレイテッド 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
WO2005070462A2 (en) 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (de) 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
WO2005123070A1 (en) 2004-06-09 2005-12-29 Fibrogen, Inc. Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy
CN100364532C (zh) 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
PT1814527E (pt) 2004-11-05 2014-01-16 Boehringer Ingelheim Int Comprimido de bicamada compreendendo telmisartan e amlodipina
US20070026026A1 (en) * 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
MX346039B (es) 2009-05-20 2017-03-03 Boehringer Ingelheim Vetmedica Gmbh Solucion farmaceutica bebible de telmisartan.

Also Published As

Publication number Publication date
CA2761576A1 (en) 2010-11-25
JP2012526856A (ja) 2012-11-01
US8871795B2 (en) 2014-10-28
KR20120015325A (ko) 2012-02-21
US20140364473A1 (en) 2014-12-11
US20190247305A1 (en) 2019-08-15
AU2010251194A1 (en) 2012-01-19
US10314782B2 (en) 2019-06-11
CA2761576C (en) 2017-08-22
AU2010251194B2 (en) 2016-02-25
NZ597049A (en) 2014-01-31
TW201109040A (en) 2011-03-16
US10537523B2 (en) 2020-01-21
EP2432452A1 (de) 2012-03-28
SG176585A1 (en) 2012-01-30
PL2432452T3 (pl) 2017-07-31
JP5612674B2 (ja) 2014-10-22
CO6470844A2 (es) 2012-06-29
US20120095069A1 (en) 2012-04-19
CL2011002926A1 (es) 2012-06-22
EP2432452B1 (de) 2016-07-27
BRPI1013037A2 (pt) 2019-09-24
ES2598490T3 (es) 2017-01-27
MX346039B (es) 2017-03-03
AR076913A1 (es) 2011-07-20
WO2010133638A1 (de) 2010-11-25
CN102458363A (zh) 2012-05-16
DK2432452T3 (en) 2016-10-10

Similar Documents

Publication Publication Date Title
MX2011007930A (es) Conjugados de insulina cristalina.
MY184985A (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
WO2010148253A3 (en) Formulations for lysosomal enzymes
GB2488500B (en) Substances for use as anti-depressants or as a learning motivation improver
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
MX2010002736A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de tinnitus coclear.
MX341838B (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos.
IN2012DN02471A (es)
PH12012501705A1 (en) Artificial sweeteners and performance
MX2011012114A (es) Solucion farmaceutica bebible de telmisartan.
MX2010002812A (es) Composiciones alimenticias que contienen extractos de melisa.
WO2011161396A3 (en) Disinfectant composition
ZA201008160B (en) Compositions for the treatment of hair loss
PH12013500371A1 (en) Therapeutic agent for pain
WO2011081408A3 (en) Imatinib dichloroacetate and anti-cancer agent comprising the same
MX2010008280A (es) Composicion para estimular la actividad de celula asesina natural.
WO2010009809A3 (de) Wirkstoffkombinationen aus anisfruchtextrakt und hyaluronsäure
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
PH12014502323A1 (en) Oral formulation
WO2012084419A3 (de) Wirkstoffkombinationen aus glucosylglyceriden und einer oder mehreren gegen kopfschuppen wirksamen substanzen
WO2011042077A3 (de) Transdermale therapeutische systeme enthaltend 4-n-butylresorcin
UA94138C2 (ru) Лечебно-профилактическое средство в форме сиропа с антистрессовым и актопротекторным действием

Legal Events

Date Code Title Description
FG Grant or registration